Yearly Archives: 2014

Vaccines Have Been Known to Prevent Disease, What if they could Treat Disease?

Traditional vaccines are designed to prevent disease; researchers are working on something new: therapeutic vaccines, vaccinations that treat a disease after you have it.

Currently, vaccine research is underway to use therapeutic vaccines to medically treat diseases such as:

HIV, Herpes, Alzheimer’s disease and cancer

Standard prevDNA Image from website header 2014entative vaccines work by helping your immune system develop immunity to a weakened or dead form of a germ. Then, when you actually come into contact with the live germ, your immune system knows how to fight it off.

While the immune system works very well most of the time, some illnesses — like cancer, HIV, and Alzheimer’s — don’t trigger an effective immune response. In the case of some cancers, the immune system simply fails to recognize the invading cells. Other viruses, like HIV, can overwhelm the immune system and shut it down before it can work.

Therapeutic vaccines would be used after a person contracts a disease, yet they would still work by boosting your own immune system’s response to an illness.

Therapeutic vaccines help by forcing the immune system to recognize a virus or cancerous cell.  One specific type of therapeutic vaccines includes:

DNA vaccines. One problem with many therapeutic vaccines is that the effects wear off. After a vaccination, the immune system might be aggressive for a while, but eventually return to normal. Some researchers hope they can inject bits of DNA into cells, instructing them to keep the immune system ready to combat the disease.


VGXI Wins 2014 Vaccine Industry Excellence (ViE) Award for Best Contract Manufacturing Organization

VGXI announced today that the corporation won the award for Best CMO at the 7th Annual ViE Awards Ceremony held at the 2014 World Vaccine Congress in Washington, D.C.

FOR IMMEDIATE RELEASE:  ViE Award Photo at WVC 2014

The Woodlands, TX – March 28, 2014 – For the second year in a row, VGXI, Inc. was awarded the title of Best Contract Manufacturing Organization (CMO) at the Annual ViE Awards Ceremony held at the World Vaccine Congress in Washington, D.C. on March 25, 2014.  VGXI is a leading provider of DNA plasmid manufacturing and development services. Dorothy Peterson, Vice President of Operations, was in attendance to accept the award on behalf of VGXI.  “VGXI does one thing, manufacture DNA plasmid, and we do it very well.  I have a dedicated team that consistently produces high quality product.” said Ms. Peterson during her acceptance.

Winners were selected on the following five categories: range of services provided, methods of improvement and introduction of new services, attention to and quality of relationships with clients, reaching of milestones and final/ongoing outcomes and building and maintaining existing and long term partnerships. The other nominees in the category for Best Contract Manufacturing Organization included Baxter’s BioPharma Solutions, Charles River Laboratories, Lonza, SAFC and SynCo BioPartners.

VGXI would also like to congratulate Inovio Pharmaceuticals for winning the 2014 ViE Award in the category of Best Therapeutic Vaccine for their VGX-3100 DNA Vaccine, manufactured by VGXI.

Additionally, VGXI launched its new website on March 21, 2014.  VGXI will be exhibiting at the 2014 BIO International Convention in San Diego, CA on June 23-26, 2014.  VGXI will be located at Booth 1305 in the Contract Services Zone, where their ViE Awards will be displayed.

About VGXI, Inc. 

VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research.  The Company has an outstanding track record of success in manufacturing plasmid products under GMP conditions for client clinical studies in the US and Europe, and its GMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible GMP production facility, and experienced development team.

About the ViE Awards 

The only awards ceremony dedicated to this industry the ViE Awards honor individuals, organizations and initiatives which have made significant contributions over the past 12 months. The ViE Awards were created to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals within the vaccine industry.

Cautionary Factors That May Affect Future Results – Materials in this Website contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements do not relate strictly to historical or current facts and can therefore be identified as such. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Media Contact:

Christy Franco, PhD

Business Development Manager

Contact

P:  281-466-3790

Logo_QualityTagline_2014_black_transparent